These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19757200)

  • 1. Effect of liver steatosis on therapeutic response in chronic hepatitis C virus genotype 1 infected patients in hungary.
    Werling K; Schaff Z; Dinya E; Tulassay Z
    Pathol Oncol Res; 2010 Jun; 16(2):149-57. PubMed ID: 19757200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
    Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
    Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
    Westin J; Lagging M; Dhillon AP; Norkrans G; Romero AI; Pawlotsky JM; Zeuzem S; Schalm SW; Verheij-Hart E; Negro F; Missale G; Neumann AU; Hellstrand K;
    J Viral Hepat; 2007 Jan; 14(1):29-35. PubMed ID: 17212641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C.
    Jian Wu Y; Shu Chen L; Gui Qiang W
    Liver Int; 2006 Mar; 26(2):166-72. PubMed ID: 16448454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.
    Reddy KR; Govindarajan S; Marcellin P; Bernstein D; Dienstag JL; Bodenheimer H; Rakela J; Messinger D; Schmidt G; Ackrill A; Hadziyannis SJ
    J Viral Hepat; 2008 Feb; 15(2):129-36. PubMed ID: 18184196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
    Lok AS; Everhart JE; Chung RT; Kim HY; Everson GT; Hoefs JC; Greenson JK; Sterling RK; Lindsay KL; Lee WM; Di Bisceglie AM; Bonkovsky HL; Ghany MG; Morishima C;
    Hepatology; 2009 Jun; 49(6):1828-37. PubMed ID: 19291787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C.
    Sanyal AJ
    Liver Int; 2011 Jan; 31 Suppl 1():23-8. PubMed ID: 21205134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between hepatic steatosis and hepatic expression of genes involved in innate immunity in patients with chronic hepatitis C.
    Toyoda H; Kumada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Kitabatake S; Murakami Y
    Cytokine; 2013 Aug; 63(2):145-50. PubMed ID: 23673288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy.
    Khattab MA; Abdel-fattah ME; Eslam M; Abdelaleem A; Abdelaleem RA; Shatat M; Ali A; Hamdy L; Tawfek H
    J Clin Gastroenterol; 2010; 44(10):707-12. PubMed ID: 20195166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin.
    Todorovska B; Joksimovic N; Caloska-Ivanova V; Dimitrova-Genadieva M; Trajkovska M; Curakova E; Kiprijanovska S; Zafirova-Ivanovska B; Serafimoski V
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Mar; 38(1):25-33. PubMed ID: 28593897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
    Liang CC; Liu CH; Chung CS; Lin CK; Su TH; Yang HC; Liu CJ; Chen PJ; Chen DS; Kao JH
    J Infect Dis; 2015 May; 211(9):1429-36. PubMed ID: 25387585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the sustained virological response in patients with chronic hepatitis C and liver steatosis.
    Piccoli Lde Z; Mattos AA; Coral GP; Mattos AZ; Santos DE
    Arq Gastroenterol; 2011; 48(3):179-85. PubMed ID: 21952702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
    Lange CM; Kutalik Z; Morikawa K; Bibert S; Cerny A; Dollenmaier G; Dufour JF; Gerlach TJ; Heim MH; Malinverni R; Müllhaupt B; Negro F; Moradpour D; Bochud PY;
    Hepatology; 2012 Apr; 55(4):1038-47. PubMed ID: 22095909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin.
    Guidi M; Muratori P; Granito A; Muratori L; Pappas G; Lenzi M; Bianchi FB
    Aliment Pharmacol Ther; 2005 Nov; 22(10):943-9. PubMed ID: 16268968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.
    Walsh MJ; Jonsson JR; Richardson MM; Lipka GM; Purdie DM; Clouston AD; Powell EE
    Gut; 2006 Apr; 55(4):529-35. PubMed ID: 16299039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy.
    Hung CH; Kuo FY; Wang JH; Lu SN; Hu TH; Chen CH; Lee CM; Eng HL
    Antivir Ther; 2006; 11(4):483-9. PubMed ID: 16856622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C recurrence: influence of serum cholesterol levels and liver steatosis on antiviral therapy.
    Testino G; Borro P
    Hepatology; 2011 Apr; 53(4):1409-10. PubMed ID: 21190159
    [No Abstract]   [Full Text] [Related]  

  • 18. HCV virological response during treatment of chronic hepatitis C is associated with liver histological improvement in patients with HCV/HIV co-infection.
    Castro G; Ramalho LN; Zucoloto S; Martinelli Ade L; Figueiredo JF
    Braz J Infect Dis; 2008 Jun; 12(3):180-5. PubMed ID: 18833400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of liver steatosis on virological response in [corrected] Italian patients with chronic hepatitis C treated with peg-interferon alpha-2b plus ribavarin.
    Fabris P; Floreani A; Carlotto A; Baldo V; Bozzola L; Giordani MT; Negro F; Rassu M; Tramarin A; de Lalla F
    Aliment Pharmacol Ther; 2005 May; 21(9):1173-8. PubMed ID: 15854181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?
    Cross TJ; Quaglia A; Nolan J; Hughes S; Harrison PM
    J Med Virol; 2010 May; 82(6):958-64. PubMed ID: 20419809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.